Feng Felix Zhou - 04 Jul 2017 Form 3 Insider Report for China SXT Pharmaceuticals, Inc. (SXTC)

Reporting relationship: Co-CEO and Director, Director
Issuer ticker: SXTC
Reported as of: 04 Jul 2017
Net transaction value: $0
SEC form: 3
Accepted by SEC: 27 Apr 2026, 16:01:37 UTC
Source filing: View source filing
Reporting owner signature: /s/ Feng Zhou

Key filing fact

Feng Felix Zhou filed Form 3 for China SXT Pharmaceuticals, Inc. (SXTC) on 27 Apr 2026.

Key facts

This page summarizes Feng Felix Zhou's Form 3 filing for China SXT Pharmaceuticals, Inc. (SXTC).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 27 Apr 2026, 16:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002129708 Primary reporting owner

Zhou Feng Felix

Relationship: Co-CEO and Director, Director
Address: NO.35 GELIAN VILLAGE, LIANGXU TOWN, JIANGYAN, CHINA
Signature: /s/ Feng Zhou
Signature date: 27 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SXTC holding

Class B Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4
Date: 04 Jul 2017
Ownership: See Footnote
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents 4 Class B Ordinary Shares held by Feng Zhou Management Limited, a British Virgin Islands company that is 100% owned by Feng Zhou, who has the power and dispositive control over such securities.